Abstract
Introduction: Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. Areas covered: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response. Expert opinion: We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses.
Original language | English (US) |
---|---|
Pages (from-to) | 55-70 |
Number of pages | 16 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 27 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2 2018 |
Externally published | Yes |
Keywords
- Hodgkin lymphoma
- PD-1
- PD-1 inhibitor
- PD-L1
- immunotherapy
- non-Hodgkin lymphoma
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)